短效、长效奥曲肽及嗅隐亭序贯应用治疗侵袭海绵窦的生长激素型垂体瘤

发布时间：2018-03-04 01:04

本文选题：奥曲肽　切入点：溴隐亭　出处：《山东医药》2017年11期 　论文类型：期刊论文

【摘要】：目的观察短效、长效奥曲肽及溴隐亭序贯应用治疗侵袭海绵窦的生长激素型垂体瘤的疗效。方法将16例侵袭海绵窦的生长激素型垂体瘤患者随机分为观察组和对照组,各8例。观察组患者先皮下注射短效奥曲肽,每次100μg,3次/d,持续1周;然后臀部肌肉深部注射长效奥曲肽,20 mg/次,每28 d注射1次,连用3次;然后口服嗅隐亭7.5 mg/d,3个月。对照组患者臀部肌肉深部注射长效奥曲肽,每次20 mg,每28 d注射1次,连用6个月。观测并比较两组患者治疗前、后的临床症状评分、血清GH谷值、血清胰岛素样生长因子1(IGF-1)、肿瘤体积。统计两组患者胃肠道不良反应发生情况及总治疗费用。结果两组患者治疗前后的临床症状评分、血清GH谷值、血清IGF-1、肿瘤体积组间比较P均0.05。观察组2例(25%)、对照组5例(62.5%)发生胃肠道不良反应,两组胃肠道不良反应发生率相比P0.05。观察组总费用为(33 000±2 000)元,对照组为(55 000±9 000)元,观察组低于对照组(P0.05)。结论短效、长效奥曲肽及溴隐亭序贯应用治疗侵袭海绵窦的生长激素型垂体瘤疗效与单用长效奥曲肽相当,但是能够避免胃肠道不良反应,减轻患者的药物经济负担。
[Abstract]:Objective to observe the efficacy of short-term, long-acting octreotide and bromocriptine in the treatment of growth hormone type pituitary adenomas invading cavernous sinus.Methods Sixteen patients with growth hormone pituitary adenoma invading cavernous sinus were randomly divided into observation group and control group. Eight patients in each group received subcutaneous injection of short-acting octreotide three times a day for one week, and then deep hip muscle injection of long-acting octreotide for 20 mg/, once every 28 days for 3 times. The patients in the control group were injected with long-acting octreotide 20 mg every 28 days for 6 months. The clinical symptom scores before and after treatment were observed and compared, and the serum GH valley values were compared between the two groups before and after treatment. Serum insulin-like growth factor (IGF-1), tumor volume, incidence of gastrointestinal adverse reactions and total cost of treatment were analyzed. Results the clinical symptom scores and serum GH valley values were measured before and after treatment in the two groups. Serum IGF-1 and tumor volume (P < 0.05). Adverse gastrointestinal reactions occurred in the observation group (n = 2) and in the control group (n = 5). The incidence of adverse gastrointestinal reactions in the two groups was higher than that in the control group (P 0.05). The total cost of the observation group was 33,000 卤2,000 yuan, and that of the control group was 55,000 卤9,000 yuan. Conclusion the short-term, long-acting octreotide and bromocriptine sequential treatment of growth hormone type pituitary adenoma invading cavernous sinus is similar to that of long-acting octreotide alone, but it can avoid the adverse effects of gastrointestinal tract. Reduce the patient's drug economic burden.
【作者单位】：昆明医科大学第一附属医院;
【基金】：云南省应用基础研究基金资助项目(2015FB051)
【分类号】：R736.4

【相似文献】